hero-gen-003

Help your patients’ goals come back into focus Discover the power of once-daily XCOPRI.1 Help your patients’ goals come back into focus Discover the power of once-daily XCOPRI.1

ref-hero-gen-003

hero-gen-004

Your patients’ goals are back on the table Offer more patients the chance at zero seizures.1 Your patients’ goals are back on the table Offer more patients the chance at zero seizures.1

ref-hero-gen-004

hero-gen-005

Fewer seizures.1 More moments. Consider what’s possible for your patients when you switch on XCOPRI.

ref-hero-gen-005

hero-eff-002

Every patient deserves their moment to shine Choose the power of once-daily XCOPRI to help light the way forward.1

ref-hero-eff-002

hero-eff-003

ref-hero-eff-003

hero-acc-002

A branded ASM with a copay comparable to the cost of generics? It’s possible with XCOPRI. ASM=anti-seizure medication.

hero-acc-003

body-tol-005

Flexibility to meet your patients’ unique needs

XCOPRI offers bottles and maintenance blister packs to help provide patients with a dose that is both tolerable and effective for them. This personalized approach may help patients reach their long-term goals.1 Pooled data from the clinical development program demonstrated that at 5 years, the majority of patients remained on treatment2:

About the analysis2: These retention data are based on Kaplan-Meier estimates of time to discontinuation of open-label XCOPRI in the pooled population from 3 clinical studies. Conclusions of long-term efficacy and safety should not be drawn based on these data. 80% of patients were on 2-3 concomitant anti-seizure medications at the start of open-label XCOPRI treatment. In this pooled population, the median duration of XCOPRI exposure was 2.8 years, with a median XCOPRI modal dose of 200 mg/day.

ref-body-tol-005

body-tit-002

Zero seizure rates were achieved within the first titration pack1,2 When starting a patient on XCOPRI, the titration schedule helps you and your patient find their effective dose in a manageable way. This allows time for you to make concomitant dosage adjustments as needed.2 Efficacy has been demonstrated within the first 1-4 weeks of XCOPRI, with use of the 12.5 mg/day-25 mg/day titration pack.1,2

of patients achieved zero seizures within Weeks 1-4 using the 12.5 mg/day-25 mg/day titration pack1,2

of patients achieved zero seizures within Weeks 1-4 using the 12.5 mg/day-25 mg/day titration pack1,2

Results from a post hoc analysis of a phase 3 study: Percentage of patients (n=125) with 1-2 seizures/28 days at baseline who achieved zero seizures within the first 4 weeks taking XCOPRI.1

ref-body-tit-002

cta-saf-002

Safety data to help you counsel patients on what to expect

cta-saf-003

Help patients stay the course to achieving their goals.

cta-saf-004

Expert insights on titration and dosage adjustments See how Dr Pavel Klein approached a challenging patient case, why he chose to add XCOPRI, and how he navigated dosing along the way. Expert insights on titration and dosage adjustments See how Dr Pavel Klein approached a challenging patient case, why he chose to add XCOPRI, and how he navigated dosing along the way.

cta-eff-002

Learn about XCOPRI’s proven seizure reduction.1

ref-cta-eff-002

cta-eff-003

Explore XCOPRI efficacy and the chance to achieve zero seizures.1

ref-cta-eff-003

cta-eff-004

Discover what patients can achieve when you switch on XCOPRI.

cta-eff-005

Expert insights on the power of zero seizures Dr Lawrence Seiden shares about how a long-term patient went from having 1 seizure every 4-6 weeks—to almost zero with XCOPRI. Expert insights on the power of zero seizures Dr Lawrence Seiden shares about how a long-term patient went from having 1 seizure every 4-6 weeks—to almost zero with XCOPRI.

cta-eff-006

Expert insights on treatment goals with XCOPRI Dr Michael Smith speaks about why his patients appreciate getting to monotherapy after often having been on many medications in their lifetime. Expert insights on treatment goals with XCOPRI Dr Michael Smith speaks about why his patients appreciate getting to monotherapy after often having been on many medications in their lifetime.

cta-eff-007

Expert insights on the impact of getting to zero Dr Pavel Klein discusses the impact of XCOPRI on his patients whose lives have been taken over by seizures. Expert insights on the impact of getting to zero Dr Pavel Klein discusses the impact of XCOPRI on his patients whose lives have been taken over by seizures.

cta-gen-007

Explore Epilepsy Connect, designed by APPs, for APPs An online destination for epilepsy education SK Life Science understands that advancement in epilepsy care never stops, which is why we are committed to innovating education and resources. Epilepsy Connect offers APPs networking, courses, and more—in the ways that work best for them. APPs=Advanced Practice Providers. Explore Epilepsy Connect, designed by APPs, for APPs An online destination for epilepsy education SK Life Science understands that advancement in epilepsy care never stops, which is why we are committed to innovating education and resources. Epilepsy Connect offers APPs networking, courses, and more—in the ways that work best for them. APPs=Advanced Practice Providers.

cta-gen-010

Laura switched on more of what matters Laura lived with 1-2 seizures/month despite 5 prior anti-seizure medications. With XCOPRI, Laura has 1 seizure/6 months and was able to return to games, family time, and even rock and roll. Laura switched on more of what matters Laura lived with 1-2 seizures/month despite 5 prior anti-seizure medications. With XCOPRI, Laura has 1 seizure/6 months and was able to return to games, family time, and even rock and roll.

cta-gen-011

Shannon got back to work and family Despite treatment with 2 anti-seizure medications, Shannon continued to experience 1 seizure/month. With XCOPRI he reports zero seizures, has returned to work, and enjoys more meaningful time with his daughters. Shannon got back to work and family Despite treatment with 2 anti-seizure medications, Shannon continued to experience 1 seizure/month. With XCOPRI he reports zero seizures, has returned to work, and enjoys more meaningful time with his daughters.

cta-gen-012

Koral returned to the classroom Koral experienced daily seizures despite 4 anti-seizure medications. After starting XCOPRI, she now reports about 1 seizure/month—a shift that has helped her return to college and continue teaching. Koral returned to the classroom Koral experienced daily seizures despite 4 anti-seizure medications. After starting XCOPRI, she now reports about 1 seizure/month—a shift that has helped her return to college and continue teaching.